ストックスクリーナーアプリを入手
3.18
4.50%
-0.15
アフターアワーズ：
3.19
0.010
+0.31%
前日終値:
$3.33
開ける：
$3.35
24時間の取引高:
592.50K
Relative Volume:
0.42
時価総額：
$155.29M
収益：
$103.00K
当期純損益:
$-42.47M
株価収益率:
-1.6737
EPS:
-1.9
ネットキャッシュフロー:
$-34.30M
1週間 パフォーマンス:
+0.63%
1か月 パフォーマンス:
-14.40%
6か月 パフォーマンス:
+19.10%
1年 パフォーマンス:
+70.97%
1日の値動き範囲:
$3.15
$3.37
1週間の範囲:
$3.11
$3.42
52週間の値動き範囲:
$1.38
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
名前
Checkpoint Therapeutics Inc
セクター
電話
781-652-4500
住所
95 SAWYER ROAD, WALTHAM, NY
CKPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
3.18 | 155.29M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-13 | 開始されました | D. Boral Capital | Buy |
| 2022-07-14 | 再開されました | B. Riley Securities | Buy |
| 2021-06-09 | 開始されました | B. Riley Securities | Buy |
| 2021-01-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-29 | 開始されました | Lake Street | Buy |
| 2017-12-08 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Checkpoint Therapeutics Inc (CKPT) 最新ニュース
Reviewing LifeVantage (NASDAQ:LFVN) & Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Checkpoint Therapeutics stock initiated at Buy Rating by Borak Capital - Investing.com Canada
This PG&E Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
D. Boral Capital Initiates Coverage of Checkpoint Therapeutics (CKPT) with Buy Recommendation - MSN
Checkpoint Therapeutics CFO signs new executive agreement By Investing.com - Investing.com Australia
Checkpoint Therapeutics CFO signs new executive agreement - Investing.com India
Geode Capital Management LLC Buys 124,787 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics Signs Executive Agreement with CFO - TipRanks
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Today’s Hot Stock - Stocks Register
State Street Corp Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics CFO sells $1.08 million in stock - Investing.com India
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares - MarketBeat
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock - MarketBeat
Checkpoint Therapeutics CFO sells $1.08 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics CEO sells $3.07 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval (NASDAQ:CKPT) - Seeking Alpha
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma - Defense World
Affimed Shares Fall 32% on Clinical Update - Yahoo Finance
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 at Lake Street Capital - Defense World
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November - MarketBeat
Investors Purchase Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
FDA Approves Cosibelimab for Cutaneous SCC - Medscape
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 - MarketBeat
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December' - Benzinga
FDA approves Checkpoint Thera’s Unloxcyt - The Pharma Letter
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Checkpoint stock on watch after FDA nod (CKPT:NASDAQ) - Seeking Alpha
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval - Marketscreener.com
Checkpoint Therapeutics Gets Its First FDA Approval - Marketscreener.com
US FDA approves Checkpoint's skin cancer drug - Reuters.com
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Absci highlights progress, updates across proprietary pipeline - Yahoo Finance
Lucid Group Inc (LCID-Q) QuotePress Release - The Globe and Mail
Nine PDUFA dates on FDA’s December calendar - BioCentury
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - cnhinews.com
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics stock hits 52-week high at $3.98 By Investing.com - Investing.com South Africa
Checkpoint Therapeutics stock hits 52-week high at $3.98 - Investing.com
Checkpoint Therapeutics Inc (CKPT) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):